Tag: medical marijuana

Fallout from the Obama Administration’s aggressive federal enforcement in medical marijuana states has reached a fever pitch this month with three people being sentenced, two others due to surrender to federal authorities to serve out sentences of up to five years in prison, and one federal trial in Montana currently scheduled for January 14th. Two of the three people being sentenced in the coming month — Montana cultivator Chris Williams and Los Angeles-area dispensary operator Aaron Sandusky — face five and ten years to life, respectively.

“The number of sick patients being locked up by the Obama Administration is unprecedented and deplorable,” said Kris Hermes, spokesperson for Americans for Safe Access, the country’s leading medical marijuana advocacy organization. “Aggressive enforcement is an unacceptable means of addressing medical marijuana as a public health issue,” continued Hermes. “The Obama Administration is lying to the American people when it says it’s not targeting individual patients and these cases are clear evidence of that.” Montana patient cultivator Richard Flor died in August while serving out a 5-year prison sentence.

Five cultivators claiming to be in compliance with Michigan’s medical marijuana law were sentenced in October. Two of the cultivators — Jaycob Montague and Jeremy Duval — are already serving their prison terms of 18 months and 5 years, respectively, and two others — John Marcinkewciz and Shelley Waldron — are scheduled to surrender to federal authorities on January 8th and 10th, respectively. Waldron will be imprisoned for 18 months and Marcinkewciz for 5 years. The fifth cultivator, Jerry Duval (Jeremy’s father), was sentenced to 10 years, but has not yet been given a surrender date.

More than a dozen people were indicted after federal agents conducted raids on state compliant medical marijuana businesses throughout Montana in March 2011. Only one, Chris Williams, went to trial and, like all other medical marijuana defendants who are tried in federal court, was denied a defense and swiftly convicted. While facing more than 80 years of mandatory minimum sentencing, Williams accepted a rare post-conviction plea deal that reduced his charges and possible sentence to 5 years to life in exchange for his promise not to appeal his conviction.

Williams, who is scheduled to be sentenced on February 1st, worked at Montana Cannabis with Chris Lindsey, another indicted cultivator. Lindsey, who testified against Williams at his trial, is expected to be sentenced today. Medical marijuana cultivator Jason Washington has one of the last unresolved federal cases in Montana. Washington is currently scheduled to go to trial on January 14th.

Aaron Sandusky operated G3 Holistic in Upland, California when he was federally indicted in June. Though Sandusky was arrested with several others, he was the only one who took his case to trial. In October, Sandusky was denied a defense in federal court and convicted at trial. He is scheduled to be sentenced on January 7th to a minimum of 10 years to life.

Far surpassing his predecessor George W. Bush, President Obama has conducted more than 200 SWAT-style raids on state-compliant medical marijuana businesses and has indicted more than 80 people since he took office.

“How many medical marijuana patients is President Obama going to imprison before he considers other, more humane options?” asked Hermes. “The president must answer for why he’s going against his earlier pledges by spending Justice Department funds in this way, especially at a time of fiscal crisis.”

Could the active ingredient in marijuana, responsible for its characteristic “high,” help turn the tide against the accelerating Alzheimer’s epidemic?

A remarkable study published in the journal Molecular Pharmacology in 2006, found that this long vilified plant contains a compound with not one, but two therapeutic properties ideal for addressing both the surface symptom (memory problems) and root cause (brain plaque) of Alzheimer’s disease.[i] This is an ironic finding, considering that the prevailing stereotype is that using marijuana “fries” the brain, leading to debilitating memory issues.

Researchers discovered that the psychoactive component of marijuana, Δ9-tetrahydrocannabinol (THC), both “competitively inhibits the enzyme acetylcholinesterase (AChE) as well as prevents AChE-induced amyloid β-peptide (Aβ) aggregation.”

On the first account, THC’s ability to inhibit the AChE enzyme, is not unlike the mechanism of action behind most Alzheimer’s drugs on the market today. Drugs like donepezil (trade name Aricept), for instance, by targeting and inhibiting the brain enzyme acetylcholinesterase (AChE), result in an increase in brain levels of this neurotransmitter, which in turn, results in symptom reduction, i.e. improved memory. Donepezil, however, is riddled with controversy due its well-known association with seizures, which likely reflects its intrinsic neurotoxicity. It is, in fact, a chemical in the same general chemical class as venom, insecticides and chemical war agents, such as nerve gas.

On the second account, THC’s ability to prevent the acetylcholinesterase-associated amyloid β-peptide (Aβ) aggregation, i.e. brain plaque, indicates that it may, as the researchers noted, “directly impact Alzheimer’s disease pathology.” In fact, they found “Compared to currently approved drugs prescribed for the treatment of Alzheimer’s disease, THC is a considerably superior inhibitor of Aβ aggregation, and this study provides a previously unrecognized molecular mechanism through which cannabinoid molecules may directly impact the progression of this debilitating disease.”

What is so encouraging about this research, and which the researchers described as “noteworthy,” is the following:

THC is a considerably more effective inhibitor of AChE-induced Aβ deposition than the approved drugs for Alzheimer’s disease treatment, donepezil and tacrine, which reduced Aβ aggregation by only 22% and 7%, respectively, at twice the concentration used in our studies.7 Therefore, AChE inhibitors such as THC and its analogues may provide an improved therapeutic for Alzheimer’s disease, augmenting acetylcholine levels by preventing neurotransmitter degradation and reducing Aβ aggregation, thereby simultaneously treating both the symptoms and progression of Alzheimer’s disease.

THC, of course, is only one of a wide range of cannabinoids in the plant marijuana. Not only is there already plentiful information on the neuroprotective properties of marijuana compounds, but there is also a sizeable body of clinical and/or biomedical research indicating the medicinal value of this plant in over 150 health conditions. To view this research visit our Medical Marijuana Research page.

Thanks to the available findings of a 2006 study showing that cannabis actually reduces the number of cancer cells, medical marijuana users can now feel even better about the widely abolished pain relief ingredient found in the plant. The relationship between marijuana and cancer has always been up for debate, but with the use of a specially crafted oil made from the buds of the Cannabis Sativa plant, scientists confirmed that the plant’s primary psychoactive chemical tetrahydrocannabinol (THC) destroys any and all malignant cancer cell growths in several patients. Details on the marijuana and cancer prevention connection aren’t exactly known, but further, more extensive testing will reveal exactly what may be causing this seemingly miracle cure.

Shedding Some Light on the Marijuana and Cancer Relationship

Back in 2006, the study was developed by a team of medical researchers at the Virginia Commonwealth University’s Pharmacology and Toxicology department on leukemia patients. The researchers essentially outlined that if taken daily for an extended period of time, cannabis oil actually reverses the growth of cancer and possibly leads to remission in the patient – with zero added side effects. Typically when a leukemia patient enters a hospital for admission and treatment, they are given a very extensive chemotherapy treatment, usually paired with a radiological treatment. Instead of considering any possible treatment involving marijuana and cancer, doctors use these not only ineffective, but also dangerous treatments. Cannabis, on the other hand, as shown in the study, has virtually no side effects. It is especially safe and effective when administered in a clean, medically sound environment and in the form of oil.

Other studies have been made over the past decades much like this one: Manuel Guzman located in Madrid, Spain discovered that cannabinoids substantially inhibit the growth of tumors in a variety of lab animals. In the study he also found that not one of these tested animals endured any kind of side effects seen in many similar chemotherapy treatments. It is becoming increasingly clear that you can sidestep any of the misery associated with traditional cancer treatments and embrace the potent, effective healing powers of THC – not to forget about the positive attributes surrounding cannabis’ other primary cannabinoid, cannabidiol (CBD).

If the results don’t appeal to you, then maybe the 2,500 total studied patients throughout these 37 controlled studies will blow the lid on the myth that cannabis is and can only be used as a “dangerous” drug. None of the patients reported any kind of adverse side effects from the use of THC and based medication – further adding to the benefits of medical marijuana and strengthening the positive connection between marijuana and cancer.

The real irony in the situation here? The combined governments of the world are the primary authority behind more than 30 studies like these completed throughout the years – and kept them secret from the general public. It wouldn’t be very conducive for our government if word got out that a schedule 1 narcotic could actually help people.

Investigators at the University of Melbourne and the Australian National University, Center for Mental Health Research assessed the impact of cannabis use on various measures of memory and intelligence in over 2,000 self-identified marijuana consumers and non-users over an eight-year period. Among cannabis consumers, subjects were grouped into the following categories: ‘heavy’ (once a week or more) users, ‘light’ users, ‘former heavy’ users, ‘former light’ users, and ‘always former’ — a category that consisted of respondents who had ceased using marijuana prior to their entry into the study.Researchers reported: “Only with respect to the immediate recall measure was there evidence of an improved performance associated with sustained abstinence from cannabis, with outcomes similar to those who had never used cannabis at the end point. On the remaining cognitive measures, after controlling for education and other characteristics, there were no significant differences associated with cannabis consumption.”

They concluded, “Therefore, the adverse impacts of cannabis use on cognitive functions either appear to be related to pre-existing factors or are reversible in this community cohort even after potentially extended periods of use.”